PubMed Health⌕ Search

Biomedical subjects

Nikorn Dusitsin

Publications and source records attributed to Nikorn Dusitsin.

2 recordsLinked to original sources

A new approach for the detection of cervical cancer in Thai women.

OBJECTIVES: The objective was to screen cervical cell samples of Thai women by using the Fourier-transform infrared (FTIR) spectrophotometry technique; the results were compared to the histologic diagnosis (gold standard). METHODS: FTIR spectrophotometry is a new technology for cervical cancer screening. Instead of detecting the morphological changes as used in Pap smear test, this technique detects, at the molecular level, structural changes of functional groups through the changes of the infrared absorption spectrum. When the infrared light is passed through a cervical cell sample, a molecule absorbs infrared radiation of the appropriate frequency which excites it from one vibrational or rotational level to another. A graph of energy absorbed versus frequency is the absorption spectrum of the sample. The FTIR spectra can be interpreted as normal and abnormal results. First, significant changes in the intensity ratios and, second, significant shifts of the peak frequencies were detected. Two hundred seventy-five cervical cell specimens were received from patients undergoing hysterectomy at the Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University Hospital. Samples were collected, prepared, and analyzed by FTIR spectroscopy. RESULTS: Histological examinations showed 108 abnormal cases and 167 normal cases. FTIR results versus histology showed sensitivity of 96.3% and specificity of 96.4%. False-negative and false-positive rates were 3.7 and 3.6%, respectively. CONCLUSIONS: FTIR showed high sensitivity and yielded a good false-negative rate. Besides the cervical cancer detection, the FTIR spectroscopy technique can also elicit positive results from adenocarcinoma of the endometrium, sarcoma of the uterus, and ovarian malignancies.

Female↗

Contraception in perimenopause.

Women in their forties are still potentially fertile, and pregnancy in this age group is attended with increased maternal mortality, spontaneous abortion, fetal anomalies and perinatal mortality. Contraception for women in this age group has special risks and benefits; both should be balanced to choose between the different options available. Recent epidemiological and clinical pharmacology studies have indicated the safety of extending the use of combined oral contraceptives (COCs) beyond the age of 35 years and up to menopause. Women who have reasons for avoiding COCs can use progestogen-only contraceptives like pills, depot injectables and implants. Implant combines high efficacy and long-term effect. Both copper-releasing and levonorgestrel-releasing intrauterine contraceptive device (LNG-IUD) combine the advantages of high efficacy and long-term effect. The reduced fecundity above the age of forty can allow extending the use beyond the accepted term, and up to one or two years beyond the menopause without the need for replacement. The levonorgestrel IUD has the advantage of reducing the amount of menstrual bleeding. The condom has the added benefit of protection against sexual transmitted diseases (STDs). Male or female sterilization is an excellent contraceptive option, provided that this approach is culturally acceptable and available at reasonable cost and low risk.

Adult↗